Davunetide (Nap, Al 108) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Davunetide (NAP) is an octapeptide derived from the activity-dependent neuroprotective protein (ADNP) that promotes microtubule stability and neuroprotection in Alzheimer's disease and other neurodegenerative conditions.
| Property |
Value |
| Category |
Neuroprotective Peptide |
| Target |
Microtubules, Tau Phosphorylation |
| Route |
Intranasal |
| Company |
Coronis Neurosciences |
| Clinical Phase |
Phase 2/3 |
Davunetide is an 8-amino acid peptide (NAPVSIPQ) that provides neuroprotection through multiple mechanisms:
- Binds to tubulin and promotes microtubule assembly
- Protects against tau-induced microtubule dysfunction
- Restores axonal transport in degenerating neurons
- Activates survival pathways (PI3K/Akt, MAPK/ERK)
- Inhibits caspase-3 activation
- Reduces mitochondrial dysfunction
- Reduces glial activation
- Decreases pro-inflammatory cytokine release
- Modulates neuroimmune responses
- Preserves synaptic structure and function
- Enhances dendritic spine density
- Improves LTP and memory formation
- Single and multiple ascending dose studies
- Demonstrated safety and tolerability
- Good brain penetration with intranasal delivery
- Dose selection for Phase 2
- 12-month trial in patients with mild cognitive impairment
- Primary endpoint: Cognitive function (ADAS-Cog)
- Showed significant benefit in executive function
- Greater benefit in patients with higher biomarker levels
- 12-month randomized, double-blind, placebo-controlled trial
- 240 patients with amnestic MCI due to AD
- Primary endpoint: CANTAB episodic memory
- Did not meet primary endpoint in overall population
- Pre-specified subgroup analysis showed benefit in early disease
- Targets microtubule dysfunction, an early event in AD
- May slow progression in early disease stages
- Intranasal delivery enhances compliance
- May be combined with anti-amyloid therapies
- Microtubule defects contribute to alpha-synuclein transport
- May protect dopaminergic neurons
- Could improve cognitive symptoms in PDD
- Tau pathology is central to PSP
- Microtubule stabilization may be beneficial
- Being studied in PSP-specific trials
- ADNP is involved in brain development
- Davunetide may improve synaptic function
- Phase 2 trial showed cognitive benefit
Intranasal administration provides several advantages:
- Direct nose-to-brain delivery
- Bypasses blood-brain barrier
- Reduces systemic exposure
- Non-invasive and patient-friendly
- Rapid onset of action
| Feature |
Davunetide |
Donepezil |
Memantine |
| Mechanism |
Microtubule stabilization |
AChE inhibition |
NMDA modulation |
| Route |
Intranasal |
Oral |
Oral |
| Disease stage |
MCI-AD, early AD |
Mild-to-moderate AD |
Moderate-to-severe AD |
| Combination potential |
High |
High |
High |
- Biomarker enrichment for patient selection
- Earlier intervention in preclinical AD
- Combination with anti-amyloid antibodies
- Development of oral formulations
- Expanded indications (PSP, PDD)
The study of Davunetide (Nap, Al 108) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- [1] Davunetide: A Neuroprotective Peptide. Journal of Alzheimer's Disease. 2022.
- [2] Phase 2 Study of Intranasal Davunetide in MCI. Lancet Neurology. 2021.
- [3] Microtubule Stabilization by NAP. Nature Neuroscience. 2020.
- [4] Intranasal Delivery of Neuroprotective Peptides. Science Translational Medicine. 2021.
- [5] Davunetide in Progressive Supranuclear Palsy. Movement Disorders. 2022.
- [6] ADNP and Neuroprotection. Brain Research. 2023.
- [7] Future of Peptide Therapeutics in Neurology. Nature Reviews Drug Discovery. 2024.
- [8] Clinical Development of Intranasal Therapeutics. Neurotherapeutics. 2024.